MedTrace Logo

Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

NCT05874310 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-05-24

No results posted yet for this study

Summary

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

Conditions

  • X-Linked Retinitis Pigmentosa

Interventions

GENETIC

FT-002

Comparison of different dosages of FT-002

Sponsors & Collaborators

  • Eye & ENT Hospital of Fudan University

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Henan Provincial People's Hospital

    collaborator OTHER

  • Frontera Therapeutics

    lead INDUSTRY

Principal Investigators

  • Gezhi Xu · Eye & ENT Hospital of Fudan University

  • Ruifang Sui · Peking Union Medical College Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
8 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2023-10-31
Completion
2027-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05874310 on ClinicalTrials.gov